- Home
- AFCG vs TLPH Comparison
AFCG vs TLPH Comparison
Compare AFCG & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFCG | TLPH |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.5M | 64.7M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AFCG | TLPH |
|---|---|---|
| Price | $3.08 | $1.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.75 | ★ $6.00 |
| AVG Volume (30 Days) | 278.0K | ★ 323.3K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | ★ 18.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.44 | $14,267.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.52 | $0.38 |
| 52 Week High | $9.60 | $1.57 |
Technical Indicators
Market Signals| Indicator | AFCG | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 42.61 |
| Support Level | $2.75 | $1.20 |
| Resistance Level | $3.53 | $1.25 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 39.74 | 5.38 |
Price Performance
Historical ComparisonAbout AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.